GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA)
- Open Access
- 10-09-2024
- Idiopathic Parkinson Disease
- Short Commentary
Published in:
- Authors
- Sabrina Katzdobler
- Georg Nübling
- Martin Klietz
- Urban M. Fietzek
- Carla Palleis
- Alexander M. Bernhardt
- Florian Wegner
- Meret Huber
- Sophia Rogozinski
- Luisa-Sophie Schneider
- Eike Jakob Spruth
- Aline Beyle
- Ina R. Vogt
- Moritz Brandt
- Niels Hansen
- Wenzel Glanz
- Kathrin Brockmann
- Annika Spottke
- Daniel C. Hoffmann
- Oliver Peters
- Josef Priller
- Jens Wiltfang
- Emrah Düzel
- Anja Schneider
- Björn Falkenburger
- Thomas Klockgether
- Thomas Gasser
- Brigitte Nuscher
- Christian Haass
- Günter Höglinger
- Johannes Levin
- Published in
- Journal of Neurology | Issue 10/2024
Abstract
Background
Multiple system atrophy (MSA), an atypical parkinsonian syndrome, is a rapidly progressive neurodegenerative disease with currently no established fluid biomarkers available. MSA is characterized by an oligodendroglial α-synucleinopathy, progressive neuronal cell loss and concomitant astrocytosis. Here, we investigate glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) as fluid biomarkers for differential diagnosis, assessment of clinical disease severity and prediction of disease progression in MSA.
Methods
GFAP and NfL levels were analyzed in plasma and CSF samples of 47 MSA patients as well as 24 Parkinson’s disease (PD) and 25 healthy controls (HC) as reference cohorts. In MSA, biomarker levels were correlated to baseline and longitudinal clinical disease severity (UMSARS scores).
Results
In MSA, GFAP levels in CSF and plasma predicted baseline clinical disease severity as indicated by UMSARS scores, while NfL levels predicted clinical disease progression as indicated by longitudinal changes in UMSARS scores. Cross-sectionally, NfL levels in CSF and plasma were significantly elevated in MSA compared to both PD and HC. Receiver operating curves (ROC) indicated high diagnostic accuracy of NfL for distinguishing MSA from PD (CSF: AUC = 0.97, 95% CI 0.90–1.00; plasma: AUC = 0.90, 95% CI 0.81–1.00).
Discussion
In MSA, GFAP shows promise as novel biomarker for assessing current clinical disease severity, while NfL might serve as biomarker for prediction of disease progression and differential diagnosis of MSA against PD.
Advertisement
- Title
- GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA)
- Authors
-
Sabrina Katzdobler
Georg Nübling
Martin Klietz
Urban M. Fietzek
Carla Palleis
Alexander M. Bernhardt
Florian Wegner
Meret Huber
Sophia Rogozinski
Luisa-Sophie Schneider
Eike Jakob Spruth
Aline Beyle
Ina R. Vogt
Moritz Brandt
Niels Hansen
Wenzel Glanz
Kathrin Brockmann
Annika Spottke
Daniel C. Hoffmann
Oliver Peters
Josef Priller
Jens Wiltfang
Emrah Düzel
Anja Schneider
Björn Falkenburger
Thomas Klockgether
Thomas Gasser
Brigitte Nuscher
Christian Haass
Günter Höglinger
Johannes Levin
- Publication date
- 10-09-2024
- Publisher
- Springer Berlin Heidelberg
- Published in
-
Journal of Neurology / Issue 10/2024
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459 - DOI
- https://doi.org/10.1007/s00415-024-12647-z
This content is only visible if you are logged in and have the appropriate permissions.
This content is only visible if you are logged in and have the appropriate permissions.
This content is only visible if you are logged in and have the appropriate permissions.
